(DNLI) – Analyst Ratings
-
Citi Starts Denali Therapeutics Inc. (DNLI) at Buy, 'Deep CNS Pipeline and Differentiated Platform Approaching Value Inflection Point'
-
JPMorgan Reinstates Denali Therapeutics Inc. (DNLI) at Overweight
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to DNLI Stock Lookup